$992 Million is the total value of Perceptive Advisors's 92 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AEGR | New | AEGERION PHARMACEUTICALS INC | $226,341,000 | – | 3,573,426 | +100.0% | 22.82% | – |
SRPT | New | SAREPTA THERAPEUTICS INC | $103,521,000 | – | 2,722,088 | +100.0% | 10.44% | – |
NBIX | New | NEUROCRINE BIOSCIENCES INC | $67,993,000 | – | 5,081,717 | +100.0% | 6.86% | – |
BIIB | New | BIOGEN IDEC INC | $49,772,000 | – | 231,282 | +100.0% | 5.02% | – |
IBB | New | ISHARES TRput | $46,843,000 | – | 269,400 | +100.0% | 4.72% | – |
ACRX | New | ACELRX PHARMACEUTICALS INC | $46,428,000 | – | 5,008,400 | +100.0% | 4.68% | – |
GILD | New | GILEAD SCIENCES INC | $40,419,000 | – | 788,360 | +100.0% | 4.08% | – |
REGN | New | REGENERON PHARMACEUTICALS | $31,328,000 | – | 139,310 | +100.0% | 3.16% | – |
TSRO | New | TESARO INC | $30,137,000 | – | 920,494 | +100.0% | 3.04% | – |
EXAS | New | EXACT SCIENCES CORP | $22,945,000 | – | 1,649,558 | +100.0% | 2.31% | – |
CSU | New | CAPITAL SR LIVING CORP | $21,305,000 | – | 891,408 | +100.0% | 2.15% | – |
VRTX | New | VERTEX PHARMACEUTICALS INC | $20,539,000 | – | 256,547 | +100.0% | 2.07% | – |
NEPT | New | NEPTUNE TECHNOLOGIES BIORESO | $17,602,000 | – | 5,422,920 | +100.0% | 1.78% | – |
SRPT | New | SAREPTA THERAPEUTICS INCput | $14,950,000 | – | 393,000 | +100.0% | 1.51% | – |
STML | New | STEMLINE THERAPEUTICS INC | $14,105,000 | – | 591,650 | +100.0% | 1.42% | – |
SNTA | New | SYNTA PHARMACEUTICALS CORP | $13,439,000 | – | 2,693,236 | +100.0% | 1.36% | – |
ACAD | New | ACADIA PHARMACEUTICALS INC | $13,188,000 | – | 726,629 | +100.0% | 1.33% | – |
SNTS | New | SANTARUS INC | $13,156,000 | – | 625,000 | +100.0% | 1.33% | – |
CELG | New | CELGENE CORP | $11,260,000 | – | 96,256 | +100.0% | 1.14% | – |
HCA | New | HCA HOLDINGS INC | $11,127,000 | – | 308,560 | +100.0% | 1.12% | – |
CHTP | New | CHELSEA THERAPEUTICS INTL LT | $10,714,000 | – | 4,658,680 | +100.0% | 1.08% | – |
SRPT | New | SAREPTA THERAPEUTICS INCcall | $10,461,000 | – | 275,000 | +100.0% | 1.06% | – |
SLXP | New | SALIX PHARMACEUTICALS INC | $9,807,000 | – | 148,250 | +100.0% | 0.99% | – |
CLVS | New | CLOVIS ONCOLOGY INC | $9,433,000 | – | 140,827 | +100.0% | 0.95% | – |
P103PS | New | NPS PHARMACEUTICALS INC | $8,498,000 | – | 562,400 | +100.0% | 0.86% | – |
SHPG | New | SHIRE PLCsponsored adr | $7,685,000 | – | 80,800 | +100.0% | 0.78% | – |
OPTR | New | OPTIMER PHARMACEUTICALS INCput | $7,184,000 | – | 496,500 | +100.0% | 0.72% | – |
AET | New | AETNA INC NEW | $7,169,000 | – | 112,825 | +100.0% | 0.72% | – |
ELN | New | ELAN PLCadr | $6,830,000 | – | 483,000 | +100.0% | 0.69% | – |
ASTX | New | ASTEX PHARMACEUTICALS INC | $6,779,000 | – | 1,649,423 | +100.0% | 0.68% | – |
SPNC | New | SPECTRANETICS CORP | $6,310,000 | – | 337,797 | +100.0% | 0.64% | – |
DYAX | New | DYAX CORP | $5,960,000 | – | 1,722,502 | +100.0% | 0.60% | – |
ATHX | New | ATHERSYS INC | $5,775,000 | – | 3,479,206 | +100.0% | 0.58% | – |
CRIS | New | CURIS INC | $4,442,000 | – | 1,392,564 | +100.0% | 0.45% | – |
KMDA | New | KAMADA LTD | $4,407,000 | – | 394,860 | +100.0% | 0.44% | – |
F113PS | New | COVIDIEN PLC | $4,242,000 | – | 67,500 | +100.0% | 0.43% | – |
SQNM | New | SEQUENOM INC | $4,148,000 | – | 985,180 | +100.0% | 0.42% | – |
NBIX | New | NEUROCRINE BIOSCIENCES INCput | $4,014,000 | – | 300,000 | +100.0% | 0.40% | – |
IMMU | New | IMMUNOMEDICS INC | $4,021,000 | – | 739,144 | +100.0% | 0.40% | – |
RPRX | New | REPROS THERAPEUTICS INC | $3,347,000 | – | 181,430 | +100.0% | 0.34% | – |
ANAC | New | ANACOR PHARMACEUTICALS INC | $3,258,000 | – | 582,835 | +100.0% | 0.33% | – |
ARNA | New | ARENA PHARMACEUTICALS INCput | $3,028,000 | – | 393,200 | +100.0% | 0.30% | – |
ITMN | New | INTERMUNE INC | $2,886,000 | – | 300,000 | +100.0% | 0.29% | – |
GILD | New | GILEAD SCIENCES INCput | $2,476,000 | – | 48,300 | +100.0% | 0.25% | – |
QCOR | New | QUESTCOR PHARMACEUTICALS INCcall | $2,272,000 | – | 50,000 | +100.0% | 0.23% | – |
CSBR | New | CHAMPIONS ONCOLOGY INC RSTD | $1,989,000 | – | 1,808,244 | +100.0% | 0.20% | – |
BDSI | New | BIODELIVERY SCIENCES INTL IN | $1,939,000 | – | 477,600 | +100.0% | 0.20% | – |
QCOR | New | QUESTCOR PHARMACEUTICALS INC | $1,917,000 | – | 42,186 | +100.0% | 0.19% | – |
NBS | New | NEOSTEM INC | $1,840,000 | – | 3,315,938 | +100.0% | 0.19% | – |
INFI | New | INFINITY PHARMACEUTICALS INC | $1,813,000 | – | 111,940 | +100.0% | 0.18% | – |
ANTH | New | ANTHERA PHARMACEUTICALS INC | $1,598,000 | – | 3,451,655 | +100.0% | 0.16% | – |
SGEN | New | SEATTLE GENETICS INCput | $1,573,000 | – | 50,000 | +100.0% | 0.16% | – |
CEMP | New | CEMPRA INC | $1,554,000 | – | 200,000 | +100.0% | 0.16% | – |
MGCD | New | MGC DIAGNOSTICS CORP | $1,457,000 | – | 174,449 | +100.0% | 0.15% | – |
VPHM | New | VIROPHARMA INC | $1,384,000 | – | 48,300 | +100.0% | 0.14% | – |
PGNX | New | PROGENICS PHARMACEUTICALS IN | $1,368,000 | – | 306,650 | +100.0% | 0.14% | – |
VICL | New | VICAL INCcall | $1,252,000 | – | 400,000 | +100.0% | 0.13% | – |
TKMR | New | TEKMIRA PHARMACEUTICALS CORP | $1,244,000 | – | 270,000 | +100.0% | 0.12% | – |
AMRN | New | AMARIN CORP PLCput | $1,119,000 | – | 193,000 | +100.0% | 0.11% | – |
CYCC | New | CYCLACEL PHARMACEUTICALS INC | $1,033,000 | – | 350,000 | +100.0% | 0.10% | – |
BMR | New | BIOMED REALTY TRUST INC | $1,012,000 | – | 50,000 | +100.0% | 0.10% | – |
ECYT | New | ENDOCYTE INC | $903,000 | – | 68,806 | +100.0% | 0.09% | – |
TBIO | New | TRANSGENOMIC INC | $883,000 | – | 2,207,500 | +100.0% | 0.09% | – |
UPI | New | UROPLASTY INC | $619,000 | – | 299,113 | +100.0% | 0.06% | – |
LPDX | New | LIPOSCIENCE INC | $575,000 | – | 82,292 | +100.0% | 0.06% | – |
MDGN | New | MEDGENICS INC | $570,000 | – | 150,000 | +100.0% | 0.06% | – |
EPZM | New | EPIZYME INC | $506,000 | – | 18,000 | +100.0% | 0.05% | – |
CUTR | New | CUTERA INC | $421,000 | – | 47,869 | +100.0% | 0.04% | – |
STEM | New | STEMCELLS INC | $382,000 | – | 231,600 | +100.0% | 0.04% | – |
KERX | New | KERYX BIOPHARMACEUTICALS INC | $374,000 | – | 50,000 | +100.0% | 0.04% | – |
SNSS | New | SUNESIS PHARMACEUTICALS INC | $301,000 | – | 58,010 | +100.0% | 0.03% | – |
ARRY | New | ARRAY BIOPHARMA INC | $88,000 | – | 19,320 | +100.0% | 0.01% | – |
NAVB | New | NAVIDEA BIOPHARMACEUTICALS Iput | $53,000 | – | 20,000 | +100.0% | 0.01% | – |
UNH | New | UNITEDHEALTH GROUP INC | $21,000 | – | 315 | +100.0% | 0.00% | – |
WOOF | New | VCA ANTECH INC | $20,000 | – | 780 | +100.0% | 0.00% | – |
HRC | New | HILL ROM HLDGS INC | $20,000 | – | 590 | +100.0% | 0.00% | – |
WCG | New | WELLCARE HEALTH PLANS INC | $21,000 | – | 385 | +100.0% | 0.00% | – |
V107SC | New | WELLPOINT INC | $21,000 | – | 255 | +100.0% | 0.00% | – |
CI | New | CIGNA CORPORATION | $21,000 | – | 290 | +100.0% | 0.00% | – |
DGX | New | QUEST DIAGNOSTICS INC | $20,000 | – | 325 | +100.0% | 0.00% | – |
OCR | New | OMNICARE INC | $20,000 | – | 425 | +100.0% | 0.00% | – |
HNGR | New | HANGER INC | $20,000 | – | 630 | +100.0% | 0.00% | – |
HLS | New | HEALTHSOUTH CORP | $20,000 | – | 695 | +100.0% | 0.00% | – |
HMA | New | HEALTH MGMT ASSOC INC NEWcl a | $20,000 | – | 1,265 | +100.0% | 0.00% | – |
MOH | New | MOLINA HEALTHCARE INC | $20,000 | – | 550 | +100.0% | 0.00% | – |
MD | New | MEDNAX INC | $21,000 | – | 225 | +100.0% | 0.00% | – |
ENDP | New | ENDO HEALTH SOLUTIONS INC | $19,000 | – | 530 | +100.0% | 0.00% | – |
AMSG | New | AMSURG CORP | $20,000 | – | 565 | +100.0% | 0.00% | – |
MDAS | New | MEDASSETS INC | $20,000 | – | 1,150 | +100.0% | 0.00% | – |
MGLN | New | MAGELLAN HEALTH SVCS INC | $20,000 | – | 365 | +100.0% | 0.00% | – |
ALR | New | ALERE INC | $20,000 | – | 800 | +100.0% | 0.00% | – |
CBMXW | New | COMBIMATRIX CORPORATION*w exp 05/01/201 | $1,000 | – | 5,000 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-08-14
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13D/A | 2024-04-17 |
SC 13D/A | 2024-04-17 |
4 | 2024-04-15 |
SC 13G/A | 2024-04-15 |
SC 13G | 2024-04-15 |
SC 13D/A | 2024-04-10 |
4 | 2024-04-08 |
4 | 2024-04-03 |
SC 13D/A | 2024-04-03 |
SC 13D | 2024-03-20 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.